Experimental Hematology & Oncology

Papers
(The H4-Index of Experimental Hematology & Oncology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
Complex roles of cAMP–PKA–CREB signaling in cancer225
CD44 as a tumor biomarker and therapeutic target190
Risk factors and outcome of COVID-19 in patients with hematological malignancies112
Research progress on dendritic cell vaccines in cancer immunotherapy71
Role of m6A writers, erasers and readers in cancer70
Engineering better chimeric antigen receptor T cells67
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients66
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC65
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–201763
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition60
Heterogeneity of the tumor immune microenvironment and its clinical relevance59
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies58
Macrophage, the potential key mediator in CAR-T related CRS55
MiRNA-mediated EMT and CSCs in cancer chemoresistance52
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment51
Breast cancer heterogeneity and its implication in personalized precision therapy50
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL47
Recent advances and challenges of bispecific antibodies in solid tumors46
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder43
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia41
Current insight into the regulation of PD-L1 in cancer38
COVID-19 vaccination associated severe immune thrombocytopenia38
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma37
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development36
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients36
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma34
Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A433
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors33
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy33
TRIM family contribute to tumorigenesis, cancer development, and drug resistance33
m6A binding protein YTHDF2 in cancer33
Increasing cure rates of solid tumors by immune checkpoint inhibitors31
0.014832973480225